MISSISSAUGA, Ontario, June 14, 2005 (PRIMEZONE) -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article by Glenn Wilkins, an AllPennyStocks.com News Reporter, this one discussing Chemokine Therapeutics Corp. (TSX:CTI), its industry and future prospects.
Wilkins notes that the Company's drugs for cancer and immune recovery are finding receptive ears; such reputable facilities as the National Cancer Institute, Memorial Sloan Kettering Institute in New York and Indiana's Walther Cancer Institute have been collaborating with and publishing their research with Chemokine's new developments. A study conducted by NCI demonstrated that the Company's CTCE-9908 decreased the spread of lung cancer in mice by 67%.
Wilkins also notes that in the U.S. alone, the pharmaceuticals market is growing by leaps and bounds. According to the IMS Health World Review for 2004, audited pharmaceutical sales grew at a 9% rate to $466.3 billion (all figures in U.S. dollars unless specified otherwise) in 2003. Worldwide sales of medications to treat low white blood cell counts in cancer and immune disorders were $3 billion in 2003, a figure projected to increase to about $4.5 billion by 2008. The full version of this special report on CTI can be found at: http://www.allpennystocks.com/apsc/can/article/cti_june_13_2005.htm
About AllPennyStocks.com:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs weekly stocks to watch, has a weekly market write-up, provides company spotlights, runs a unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, Nasdaq and OTC BB, and much more information for the average investor.
Although the majority of AllPennyStocks.com reports are independent, it has received compensation for carrying the report on Chemokine Therapeutics Corp. (TSX:CTI), the compensation is seven thousand seven hundred dollars from the company. This creates an inherent conflict of interest and readers are encouraged to view the full disclaimer at http://www.allpennystocks.com/apsc/can/stock_profiles/cti.htm